HRP20180813T1 - Heteroaril amidi kao inhibitori proteinske agregacije - Google Patents
Heteroaril amidi kao inhibitori proteinske agregacijeInfo
- Publication number
- HRP20180813T1 HRP20180813T1 HRP20180813TT HRP20180813T HRP20180813T1 HR P20180813 T1 HRP20180813 T1 HR P20180813T1 HR P20180813T T HRP20180813T T HR P20180813TT HR P20180813 T HRP20180813 T HR P20180813T HR P20180813 T1 HRP20180813 T1 HR P20180813T1
- Authority
- HR
- Croatia
- Prior art keywords
- amidi
- heteroaryl
- inhibitors
- protein aggregation
- aggregation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461933246P | 2014-01-29 | 2014-01-29 | |
| US201462078895P | 2014-11-12 | 2014-11-12 | |
| PCT/US2015/013263 WO2015116663A1 (en) | 2014-01-29 | 2015-01-28 | Heteroarly amides as inhibitors of protein aggregation |
| EP15705417.2A EP3099684B8 (en) | 2014-01-29 | 2015-01-28 | Heteroaryl amides as inhibitors of protein aggregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180813T1 true HRP20180813T1 (hr) | 2018-07-27 |
Family
ID=52484559
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180813TT HRP20180813T1 (hr) | 2014-01-29 | 2015-01-28 | Heteroaril amidi kao inhibitori proteinske agregacije |
| HRP20201107TT HRP20201107T8 (hr) | 2014-01-29 | 2020-07-14 | Heteroaril amidi kao inhibitori proteinske agregacije |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201107TT HRP20201107T8 (hr) | 2014-01-29 | 2020-07-14 | Heteroaril amidi kao inhibitori proteinske agregacije |
Country Status (38)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ722487A (en) | 2014-01-29 | 2022-04-29 | Ucb Biopharma Sprl | Heteroaryl amides as inhibitors of protein aggregation |
| EP3328379B1 (en) * | 2015-07-29 | 2021-07-28 | UCB Biopharma SRL | Bis-heteroaryl derivatives as modulators of protein aggregation |
| CN106474121B (zh) * | 2016-11-25 | 2017-10-10 | 刘淑兰 | 一种治疗慢性盆腔炎的药物 |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| RU2019126170A (ru) * | 2017-01-26 | 2021-02-26 | Юсб Байофарма Спрл | Бисгетероарильные производные в качестве модуляторов агрегации белков |
| JP7073385B2 (ja) * | 2017-01-26 | 2022-05-23 | ユーシービー バイオファルマ エスアールエル | タンパク質凝集のモジュレーターとしての二環式ビス－ヘテロアリール誘導体 |
| EP3573981B1 (en) * | 2017-01-26 | 2022-03-16 | UCB Biopharma SRL | Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation |
| EP3634403B1 (en) * | 2017-05-12 | 2025-06-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma |
| CA3108484A1 (en) | 2017-08-04 | 2019-02-07 | Anthony Stewart Campbell | Inhibitors of microbially induced amyloid |
| CA3079831A1 (en) * | 2017-10-31 | 2019-05-09 | Loma Linda University | Methods for treating traumatic brain injury |
| US11707452B2 (en) | 2018-08-20 | 2023-07-25 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
| EP4458824A4 (en) | 2021-12-27 | 2025-12-24 | Shanghai Jingxin Biomedical Co Ltd | Fused bicyclic heteroarylamide compound useful as a protein aggregation inhibitor |
| GB202213796D0 (en) * | 2022-09-21 | 2022-11-02 | Wista Lab Ltd | Tau aggregation inhibitors |
| EP4611895A1 (en) * | 2022-11-02 | 2025-09-10 | AC Immune SA | Novel compounds for the diagnosis of tdp-43 proteinopathies |
| WO2024184179A1 (en) | 2023-03-06 | 2024-09-12 | UCB Biopharma SRL | Minzasolmin for use in the treatment of parkinson's disease |
| WO2024184180A1 (en) | 2023-03-06 | 2024-09-12 | UCB Biopharma SRL | Minzasolmin for use in the treatment of parkinson's disease |
| WO2025002040A1 (zh) * | 2023-06-25 | 2025-01-02 | 上海京新生物医药有限公司 | 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1463997A (en) * | 1995-12-22 | 1997-07-17 | Acea Pharmaceuticals, Inc. | Subtype-selective nmda receptor ligands and the use thereof |
| EA200500721A1 (ru) * | 2002-11-28 | 2005-12-29 | Шеринг Акциенгезельшафт | Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств |
| CN101385722A (zh) * | 2003-02-27 | 2009-03-18 | 乔安妮·麦克劳林 | 预防、治疗和诊断蛋白聚集疾病的方法 |
| PL1697371T3 (pl) * | 2003-12-19 | 2007-09-28 | Bristol Myers Squibb Co | Azabicykliczne heterocykle jako modulatory receptora kanabinoidowego |
| TW200528455A (en) * | 2003-12-19 | 2005-09-01 | Bristol Myers Squibb Co | Azabicyclic heterocycles as cannabinoid receptor modulators |
| KR20070018824A (ko) * | 2003-12-19 | 2007-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클 |
| EA013678B1 (ru) * | 2004-08-26 | 2010-06-30 | Пфайзер Инк. | Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы |
| CA2580725A1 (en) * | 2004-09-20 | 2006-03-30 | 4Sc Ag | Novel heterocyclic nf-kb inhibitors |
| SE0403119D0 (sv) * | 2004-12-21 | 2004-12-21 | Astrazeneca Ab | Therapeutic agents |
| US20100168102A9 (en) | 2005-07-11 | 2010-07-01 | Devgen Nv | Amide Derivatives as Kinase Inhibitors |
| SG172738A1 (en) * | 2005-07-29 | 2011-07-28 | 4Sc Ag | Novel heterocyclic nf-kb inhibitors |
| JP2009529555A (ja) * | 2006-03-15 | 2009-08-20 | ４エスツェー アクチェンゲゼルシャフト | 新規複素環式ＮＦ−κＢ阻害薬 |
| EP2081892A4 (en) * | 2006-11-17 | 2014-03-05 | Donald F Weaver | COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE |
| WO2008157425A2 (en) * | 2007-06-14 | 2008-12-24 | The Regents Of The University Of California | Compounds for inhibiting protein aggregation, and methods for making and using them |
| US8598356B2 (en) * | 2008-11-25 | 2013-12-03 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| GB0910003D0 (en) * | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| WO2011048525A1 (en) | 2009-10-20 | 2011-04-28 | Pfizer Inc. | Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators |
| JP5922031B2 (ja) | 2009-12-16 | 2016-05-24 | ニューロポア セラピーズ，インコーポレイティド | 化合物 |
| GB201021103D0 (en) | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
| WO2013134371A1 (en) | 2012-03-06 | 2013-09-12 | Neuropore Therapies, Inc. | Methods and compounds to be used in the treatment of neurodegenerative diseases |
| KR20150002713A (ko) | 2012-03-28 | 2015-01-07 | 뉴로포레 테라피스, 인코포레이티드 | 단백질 응집 저해제로서의 페닐-우레아 및 페닐-카바메이트 유도체 |
| JP2015522617A (ja) | 2012-07-16 | 2015-08-06 | ニューロポア セラピーズ，インコーポレイティド | タンパク質凝集の阻害剤としてのジ−およびトリ−ヘテロアリール誘導体 |
| NZ722487A (en) | 2014-01-29 | 2022-04-29 | Ucb Biopharma Sprl | Heteroaryl amides as inhibitors of protein aggregation |
| EP3328379B1 (en) | 2015-07-29 | 2021-07-28 | UCB Biopharma SRL | Bis-heteroaryl derivatives as modulators of protein aggregation |
| RU2019126170A (ru) | 2017-01-26 | 2021-02-26 | Юсб Байофарма Спрл | Бисгетероарильные производные в качестве модуляторов агрегации белков |
| JP7073385B2 (ja) | 2017-01-26 | 2022-05-23 | ユーシービー バイオファルマ エスアールエル | タンパク質凝集のモジュレーターとしての二環式ビス－ヘテロアリール誘導体 |
-
2015
- 2015-01-28 NZ NZ722487A patent/NZ722487A/en unknown
- 2015-01-28 SI SI201531297T patent/SI3348556T1/sl unknown
- 2015-01-28 SI SI201530252T patent/SI3099684T1/en unknown
- 2015-01-28 BR BR122018001892-5A patent/BR122018001892B1/pt active IP Right Grant
- 2015-01-28 HR HRP20180813TT patent/HRP20180813T1/hr unknown
- 2015-01-28 WO PCT/US2015/013263 patent/WO2015116663A1/en not_active Ceased
- 2015-01-28 RS RS20200827A patent/RS60547B1/sr unknown
- 2015-01-28 ES ES18156929T patent/ES2808978T3/es active Active
- 2015-01-28 SM SM20180318T patent/SMT201800318T1/it unknown
- 2015-01-28 KR KR1020167023810A patent/KR102383038B1/ko active Active
- 2015-01-28 EA EA201691529A patent/EA032374B1/ru unknown
- 2015-01-28 PL PL15705417T patent/PL3099684T3/pl unknown
- 2015-01-28 EP EP15705417.2A patent/EP3099684B8/en active Active
- 2015-01-28 ME MEP-2020-148A patent/ME03800B/me unknown
- 2015-01-28 TR TR2018/09440T patent/TR201809440T4/tr unknown
- 2015-01-28 PL PL18156929T patent/PL3348556T3/pl unknown
- 2015-01-28 HK HK17105014.2A patent/HK1231470A1/zh unknown
- 2015-01-28 AU AU2015211119A patent/AU2015211119B2/en active Active
- 2015-01-28 PT PT15705417T patent/PT3099684T/pt unknown
- 2015-01-28 LT LTEP18156929.4T patent/LT3348556T/lt unknown
- 2015-01-28 LT LTEP15705417.2T patent/LT3099684T/lt unknown
- 2015-01-28 JP JP2016549488A patent/JP6619741B2/ja active Active
- 2015-01-28 EP EP18156929.4A patent/EP3348556B1/en active Active
- 2015-01-28 DK DK15705417.2T patent/DK3099684T3/en active
- 2015-01-28 HU HUE18156929A patent/HUE050964T2/hu unknown
- 2015-01-28 RS RS20180644A patent/RS57533B1/sr unknown
- 2015-01-28 CN CN201580017216.1A patent/CN106132960B/zh active Active
- 2015-01-28 HU HUE15705417A patent/HUE040274T2/hu unknown
- 2015-01-28 PE PE2016001285A patent/PE20161393A1/es unknown
- 2015-01-28 SM SM20200376T patent/SMT202000376T1/it unknown
- 2015-01-28 DK DK18156929.4T patent/DK3348556T3/da active
- 2015-01-28 BR BR112016017344-9A patent/BR112016017344B1/pt active IP Right Grant
- 2015-01-28 CN CN201911278647.XA patent/CN111039939B/zh active Active
- 2015-01-28 ES ES15705417.2T patent/ES2675301T3/es active Active
- 2015-01-28 CA CA2937967A patent/CA2937967C/en active Active
- 2015-01-28 MY MYPI2016001401A patent/MY187450A/en unknown
- 2015-01-28 SG SG11201606108RA patent/SG11201606108RA/en unknown
- 2015-01-28 AP AP2016009347A patent/AP2016009347A0/en unknown
- 2015-01-28 PT PT181569294T patent/PT3348556T/pt unknown
- 2015-01-28 CR CR20160394A patent/CR20160394A/es unknown
- 2015-01-28 UA UAA201609003A patent/UA118209C2/uk unknown
- 2015-01-28 MX MX2016009896A patent/MX2016009896A/es active IP Right Grant
- 2015-12-29 US US14/983,243 patent/US9738635B2/en active Active
-
2016
- 2016-07-27 IL IL246987A patent/IL246987B/en unknown
- 2016-07-28 ZA ZA2016/05246A patent/ZA201605246B/en unknown
- 2016-07-28 SA SA516371579A patent/SA516371579B1/ar unknown
- 2016-07-28 CL CL2016001918A patent/CL2016001918A1/es unknown
- 2016-07-28 PH PH12016501493A patent/PH12016501493B1/en unknown
- 2016-08-29 EC ECIEPI201670327A patent/ECSP16070327A/es unknown
-
2017
- 2017-08-01 US US15/666,503 patent/US10358443B2/en active Active
-
2018
- 2018-06-15 CY CY20181100630T patent/CY1120348T1/el unknown
-
2019
- 2019-06-04 JP JP2019104159A patent/JP6783900B2/ja active Active
- 2019-06-11 US US16/438,348 patent/US11078196B2/en active Active
-
2020
- 2020-07-14 HR HRP20201107TT patent/HRP20201107T8/hr unknown
- 2020-07-24 CY CY20201100682T patent/CY1123374T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201107T8 (hr) | Heteroaril amidi kao inhibitori proteinske agregacije | |
| DK3119772T3 (da) | Heteroaryl syk-hæmmere | |
| PL3167096T3 (pl) | Dwuetapowy sposób nanoszenia | |
| ME03580B (me) | Ciklopropilamini kao lsd1 inhibitori | |
| UA125061C2 (uk) | Сполуки гетероарилу як інгібітори ткб і їх застосування | |
| DK3160994T3 (da) | Multispecifikke antigenbindende proteiner | |
| HUE042335T2 (hu) | ROR-gamma dihidropirrolopiridin inhibitorai | |
| LT3071046T (lt) | Žirnių baltymų ekstrahavimo būdas | |
| LT3237432T (lt) | Baltymo gamyba | |
| DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
| DK3114120T3 (da) | Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere | |
| DK3099791T3 (da) | Protein | |
| PL3227325T3 (pl) | Selektywne kompozycje inhibitorów trans-sygnałowania il-6 | |
| DK3143018T3 (da) | Carboxamidderivater | |
| LT3212237T (lt) | Metotreksato vaistinė forma | |
| HRP20181441T1 (hr) | Inhibitori sintaze aldosterona | |
| HRP20182029T1 (hr) | Uti-fuzijski proteini | |
| EP3137649C0 (en) | METALLIZATION OF SURFACES | |
| DK3099793T3 (da) | Protein | |
| FR3024647B1 (fr) | Transat de puericulture | |
| LT3253772T (lt) | Diosmino ruošimo būdas | |
| PL3350308T3 (pl) | Zastosowanie włókna liocelowego | |
| PL3237368T3 (pl) | Sposób oczyszczania laktylanu | |
| LT3183264T (lt) | Pegilinimo būdas | |
| GB201415425D0 (en) | Small molecule inhibitors of classiv bromodomain proteins |